Adjuvant bacillus Calmette-Guérin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naïve high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study

International Immunopharmacology 2026

View at publisher

Authors: Tianyuan Xu, Keyi Wang, Yifan Chen, Yang Yu, Wentao Zhang, Danjing Shen, Jingcheng Zhang, Jiang Geng, Bo Peng, Yang Yan, Xudong Yao

DOI: 10.1016/j.intimp.2026.116186

Cited by: 1

References: 35

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Immune responses and vaccinations Urinary and Genital Oncology Studies

References 35